Company: DVAX
Filing Date: 2025-05-19
Form Type: DFAN14A
Source: 0001193125-25-122435
Chunk: 6

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-19
Form: DFAN14A
Chunk 6
---
33285 6/7/2022 COMPLETED COVID-19 PT Bio Farma PHASE3 4050 NCT04843852 07/2022 WITHDRAWN Hepatitis B University of Maryland, Baltimore PHASE1 0 NCT05506969 8/9/2022 COMPLETED Plague, Pneumonic|Plague|Vaccine-Preventable Diseases Dynavax Technologies Corporation PHASE2 200 NCT05298644 10/1/2022 WITHDRAWN SARS-CoV-2 Infection Valneva Austria GmbH PHASE2|PHASE3 0 NCT05545683 12/1/2022 WITHDRAWN COVID-19 Centro de Estudios en InfectogÃa Pediatrica PHASE3 0 NCT05606341 3/13/2023 RECRUITING Mild Cognitive Impairment|Alzheimer Dementia NYU Langone Health PHASE1 15 AIDS/HIV - RelatedDisease Associated With AIDS|Vaccine-Preventable Diseases|HIV NCT06541093 1/30/2024 ACTIVE_NOT_RECRUITING Infections Uvax Bio LLC EARLY_PHASE1 34 NCT06334393 03/25/2024 ACTIVE_NOT_RECRUITING Zika|Zika Virus Infection Valneva Austria GmbH PHASE1 150 Source: clinicaltrials.gov 6

The CpG 1018 Value Opportunity Has Already Proven to Be Highly Uncertain After 20+ years, CpG 1018 is used in only one FDA-approved vaccine The current Board has only overseen failures in pipeline development: x It failed to win an indication for Heplisav for hemodialysis after 20 years of development efforts. x It failed with the TDAP program. CpG 1018 provided a one-time revenue spike from COVID supply deals (2020-2022) but has generated $0 since in sales or partnerships. 1 once-in-a- - CEO Ryan Spencer, March 4, 2024 The value opportunity for CpG 1018 is limited and uncertain CpG 1018 is not approved for pediatric use, which is when the vast majority of vaccines are administered. effective). The vaccine development community is a small one and CpG 1018 is no secret. We believe if the bigger players in the space thought combining CpG 1018 with their own vaccine programs was compelling, they would have approached Dynavax